EXEL Exelixis Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: EXEL

Price (delayed)

$23.39

Market cap

$6.81B

P/E Ratio

36.55

Dividend/share

N/A

EPS

$0.64

Enterprise value

$6.76B

Founded in 1994, Exelixis, Inc. is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work ...

Highlights
The company's net income rose by 33% YoY
The company's EPS rose by 33% YoY
EXEL's quick ratio is down by 32% year-on-year but it is up by 3.2% since the previous quarter
The company's equity fell by 17% YoY and by 6% QoQ
The debt has increased by 8% YoY and by 6% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.exelixis.com
Peers: MRK BMY AMGN CRIS

Key stats

What are the main financial stats of EXEL
Market
Shares outstanding
291.29M
Market cap
$6.81B
Enterprise value
$6.76B
Valuations
Price to earnings (P/E)
36.55
Price to book (P/B)
3.33
Price to sales (P/S)
3.81
EV/EBIT
26.13
EV/EBITDA
21.6
EV/Sales
3.66
Earnings
Revenue
$1.85B
EBIT
$258.51M
EBITDA
$312.76M
Free cash flow
$279.6M
Per share
EPS
$0.64
Free cash flow per share
$0.93
Book value per share
$7.02
Revenue per share
$6.14
TBVPS
$9.11
Balance sheet
Total assets
$2.8B
Total liabilities
$675.74M
Debt
$201.47M
Equity
$2.13B
Working capital
$919.42M
Liquidity
Debt to equity
0.09
Current ratio
3.46
Quick ratio
3.23
Net debt/EBITDA
-0.19
Margins
EBITDA margin
16.9%
Gross margin
95.7%
Net margin
11.1%
Operating margin
9.3%
Efficiency
Return on assets
6.9%
Return on equity
8.9%
Return on invested capital
10.9%
Return on capital employed
10.6%
Return on sales
14%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EXEL stock price

How has the Exelixis stock price performed over time
Intraday
1.87%
1 week
3.5%
1 month
4.51%
1 year
18.01%
YTD
-2.5%
QTD
4.09%

Financial performance

How have Exelixis's revenue and profit performed over time
Revenue
$1.85B
Gross profit
$1.77B
Operating income
$171.52M
Net income
$205.05M
Gross margin
95.7%
Net margin
11.1%
The company's net income rose by 33% YoY
The net margin has increased by 21% YoY but it has decreased by 2.6% from the previous quarter
Exelixis's operating income has increased by 17% YoY
The revenue has grown by 11% YoY

Growth

What is Exelixis's growth rate over time

Valuation

What is Exelixis stock price valuation
EXEL P/E details
P/E
36.55
P/B
3.33
P/S
3.81
EV/EBIT
26.13
EV/EBITDA
21.6
EV/Sales
3.66
The company's EPS rose by 33% YoY
The P/E is 24% below the last 4 quarters average of 47.4 and 6% below the 5-year quarterly average of 38.1
The company's equity fell by 17% YoY and by 6% QoQ
EXEL's P/B is 9% above its 5-year quarterly average of 3.0 and 9% above its last 4 quarters average of 3.0
EXEL's price to sales (P/S) is 24% lower than its 5-year quarterly average of 4.9 and 4.1% lower than its last 4 quarters average of 3.9
The revenue has grown by 11% YoY

Efficiency

How efficient is Exelixis business performance
The company's return on equity rose by 44% YoY and by 3.5% QoQ
The ROA has grown by 35% YoY
The ROIC has grown by 22% YoY
The company's return on sales rose by 18% YoY

Dividends

What is EXEL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EXEL.

Financial health

How did Exelixis financials performed over time
EXEL's quick ratio is down by 32% year-on-year but it is up by 3.2% since the previous quarter
EXEL's current ratio is down by 31% year-on-year but it is up by 3.6% since the previous quarter
The debt is 91% less than the equity
The company's debt to equity rose by 29% YoY and by 13% QoQ
The company's equity fell by 17% YoY and by 6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.